DefEYE is a technology company.
DefEYE has raised $12.0M across 1 funding round.
DefEYE has raised $12.0M in total across 1 funding round.
DefEYE has raised $12.0M in total across 1 funding round.
DefEYE's investors include ExSight Capital Management.
DefEYE, Inc. is a technology company specializing in ophthalmic biologic solutions designed to improve the treatment and management of ocular surface diseases and support recovery after ocular surgery. It serves eye care professionals such as ophthalmologists and optometrists by providing a portfolio of innovative, decellularized biologic products, including the Biovance franchise, which are unique in their category for ocular applications. The company is experiencing strong growth momentum, with sales increasing nearly 70% year-over-year in 2024, reflecting accelerating adoption of regenerative therapies in eye care[1][2][3].
DefEYE officially launched as an independent company on October 1, 2025, evolving from Verséa Ophthalmics, a subsidiary of Verséa Health, Inc. The company was founded to expand the commercial foundation established by Verséa Ophthalmics. Its leadership includes CEO Dr. Rob Sambursky, a Wills Eye-trained corneal specialist and entrepreneur with a track record in diagnostic and therapeutic eye care platforms. The company’s early traction is marked by strong sales growth and strategic partnerships, notably with Celularity, which invested in DefEYE’s $12 million Series Seed Preferred Equity round and entered an exclusive licensing and pricing agreement to advance regenerative therapies in eye care[1][2].
DefEYE is positioned at the intersection of regenerative medicine and ophthalmology, riding the trend of biologic therapies that offer alternatives to traditional pharmaceuticals and surgical interventions. The timing is favorable due to growing demand for advanced treatments for ocular surface diseases and post-surgical recovery, alongside increasing acceptance of regenerative biologics in clinical practice. Market forces such as an aging population and rising prevalence of eye conditions further support growth. DefEYE’s innovations contribute to expanding the ecosystem of regenerative eye care solutions, influencing both clinical practice and product development in ophthalmology[1][2].
Looking ahead, DefEYE is poised to scale its product portfolio and market presence, leveraging its strategic partnership with Celularity and ongoing education efforts targeting eye care professionals. Trends shaping its journey include broader adoption of regenerative therapies, advances in biologic manufacturing, and increasing integration of personalized medicine in ophthalmology. As DefEYE expands, it may become a key player driving the transformation of eye care through biologic innovation, potentially influencing standards of care and opening new therapeutic avenues. This trajectory ties back to its foundation as a specialized, clinically driven company focused on addressing unmet needs in ocular health with cutting-edge biologic solutions[1][2].
DefEYE has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $12.0M Seed | ExSight Capital Management |